CR20220092A - Síntesis de un inhibidor de calicreína plasmática a escala de proceso - Google Patents

Síntesis de un inhibidor de calicreína plasmática a escala de proceso

Info

Publication number
CR20220092A
CR20220092A CR20220092A CR20220092A CR20220092A CR 20220092 A CR20220092 A CR 20220092A CR 20220092 A CR20220092 A CR 20220092A CR 20220092 A CR20220092 A CR 20220092A CR 20220092 A CR20220092 A CR 20220092A
Authority
CR
Costa Rica
Prior art keywords
plasma kallikrein
scale synthesis
kallikrein inhibitor
inhibitor
scale
Prior art date
Application number
CR20220092A
Other languages
English (en)
Inventor
Yarlagadda S Babu
Yahya El-Kattan
Original Assignee
Biocryst Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocryst Pharm Inc filed Critical Biocryst Pharm Inc
Publication of CR20220092A publication Critical patent/CR20220092A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C253/00—Preparation of carboxylic acid nitriles
    • C07C253/30—Preparation of carboxylic acid nitriles by reactions not involving the formation of cyano groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physical Or Chemical Processes And Apparatus (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Steroid Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Métodos para preparar el Compuesto I, y sus sales. Dichos métodos de preparación del Compuesto I son apropiados para usar a escala de proceso. <!--[if gte vml 1]><v:shapetype id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f"> <v:stroke joinstyle="miter"/> <v:formulas> <v:f eqn="if lineDrawn pixelLineWidth 0"/> <v:f eqn="sum @0 1 0"/> <v:f eqn="sum 0 0 @1"/> <v:f eqn="prod @2 1 2"/> <v:f eqn="prod @3 21600 pixelWidth"/> <v:f eqn="prod @3 21600 pixelHeight"/> <v:f eqn="sum @0 0 1"/> <v:f eqn="prod @6 1 2"/> <v:f eqn="prod @7 21600 pixelWidth"/> <v:f eqn="sum @8 21600 0"/> <v:f eqn="prod @7 21600 pixelHeight"/> <v:f eqn="sum @10 21600 0"/> </v:formulas> <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/> <o:lock v:ext="edit" aspectratio="t"/></v:shapetype><v:shape id="Imagen_x0020_42" o:spid="_x0000_i1025" type="#_x0000_t75" alt="" style='width:172.5pt;height:117pt'> <v:imagedata o:href="cid:image010.png@01D82F0C.33E22000"/></v:shape><![endif]--> I.
CR20220092A 2019-08-06 2020-08-05 Síntesis de un inhibidor de calicreína plasmática a escala de proceso CR20220092A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962883396P 2019-08-06 2019-08-06
PCT/US2020/044921 WO2021026182A1 (en) 2019-08-06 2020-08-05 Process-scale synthesis of a plasma kallikrein inhibitor

Publications (1)

Publication Number Publication Date
CR20220092A true CR20220092A (es) 2022-06-03

Family

ID=74504082

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20220092A CR20220092A (es) 2019-08-06 2020-08-05 Síntesis de un inhibidor de calicreína plasmática a escala de proceso

Country Status (20)

Country Link
US (1) US20220289683A1 (es)
EP (1) EP4010320A4 (es)
JP (1) JP2022543419A (es)
KR (1) KR20220044276A (es)
CN (1) CN114206839A (es)
AR (1) AR119617A1 (es)
AU (1) AU2020324422A1 (es)
BR (1) BR112022002060A2 (es)
CA (1) CA3149176A1 (es)
CL (2) CL2022000264A1 (es)
CO (1) CO2022002392A2 (es)
CR (1) CR20220092A (es)
EC (1) ECSP22016209A (es)
IL (1) IL290113A (es)
JO (1) JOP20220021A1 (es)
MX (1) MX2022001608A (es)
PE (1) PE20221009A1 (es)
TW (1) TW202120481A (es)
UY (1) UY38826A (es)
WO (1) WO2021026182A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3113772T3 (pl) 2014-03-07 2021-04-06 Biocryst Pharmaceuticals, Inc. Pirazole podstawiane trifluorometylem jako inhibitory ludzkiej kalikreiny osoczowej

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
LU86084A1 (fr) 1985-09-20 1987-04-02 Faco Sa Apparei de massage electrique
US5102417A (en) 1985-11-07 1992-04-07 Expandable Grafts Partnership Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft
US4800882A (en) 1987-03-13 1989-01-31 Cook Incorporated Endovascular stent and delivery system
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4886062A (en) 1987-10-19 1989-12-12 Medtronic, Inc. Intravascular radially expandable stent and method of implant
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
WO1990013332A1 (en) 1989-05-11 1990-11-15 Cedars-Sinai Medical Center Stent with sustained drug delivery
EP0470246B1 (en) 1990-02-28 1995-06-28 Medtronic, Inc. Intralumenal drug eluting prosthesis
US5419760A (en) 1993-01-08 1995-05-30 Pdt Systems, Inc. Medicament dispensing stent for prevention of restenosis of a blood vessel
US5429634A (en) 1993-09-09 1995-07-04 Pdt Systems Biogenic implant for drug delivery and method
US6774278B1 (en) 1995-06-07 2004-08-10 Cook Incorporated Coated implantable medical device
AU2002319814A1 (en) * 2001-08-13 2003-03-03 E.I. Du Pont De Nemours And Company Substituted 1h-dihydropyrazoles, their preparation and use
US6770729B2 (en) 2002-09-30 2004-08-03 Medtronic Minimed, Inc. Polymer compositions containing bioactive agents and methods for their use
KR20160148046A (ko) * 2008-12-18 2016-12-23 바이엘 인텔렉쳐 프로퍼티 게엠베하 살해충제로서의 테트라졸 치환된 안트라닐산 아미드
PL3113772T3 (pl) * 2014-03-07 2021-04-06 Biocryst Pharmaceuticals, Inc. Pirazole podstawiane trifluorometylem jako inhibitory ludzkiej kalikreiny osoczowej

Also Published As

Publication number Publication date
TW202120481A (zh) 2021-06-01
CO2022002392A2 (es) 2022-04-08
WO2021026182A1 (en) 2021-02-11
JOP20220021A1 (ar) 2023-01-30
EP4010320A1 (en) 2022-06-15
AR119617A1 (es) 2021-12-29
ECSP22016209A (es) 2022-06-30
CL2023000942A1 (es) 2023-11-24
CN114206839A (zh) 2022-03-18
JP2022543419A (ja) 2022-10-12
AU2020324422A1 (en) 2022-03-17
US20220289683A1 (en) 2022-09-15
KR20220044276A (ko) 2022-04-07
EP4010320A4 (en) 2023-08-16
PE20221009A1 (es) 2022-06-15
MX2022001608A (es) 2022-03-11
UY38826A (es) 2021-02-26
IL290113A (en) 2022-03-01
CA3149176A1 (en) 2021-02-11
BR112022002060A2 (pt) 2022-06-07
CL2022000264A1 (es) 2022-10-21

Similar Documents

Publication Publication Date Title
MX2022007969A (es) Inhibidores de egfr.
MX2022001829A (es) Proceso de fabricación de moduladores de regulador de conductancia transmembrana de la fibrosis quística (cftr).
TN2019000263A1 (en) Macrocyclic compounds as ros1 kinase inhibitors
MX2020005484A (es) Formas solidas de un inhibidor de calicreina en plasma y sales del mismo.
WO2018086591A8 (zh) 吡啶胺取代的杂三环化合物、其制法与医药上的用途
GEP20207111B (en) Heteroaryl compounds for kinase inhibition
CL2023002956A1 (es) Inhibidor de la proteasa 1 específica de ubiquitina (usp1)
EA202193015A1 (ru) Ингибиторы cdk
MX2022000318A (es) Indanos como inhibidores de pd-l1.
PH12021550883A1 (en) Crystalline salts of a plasma kallikrein inhibitor
CR20220092A (es) Síntesis de un inhibidor de calicreína plasmática a escala de proceso
MX2022002017A (es) Metodo para producir derivado de heterociclideno acetamida.
EP4335500A3 (en) Methods for the synthesis of deuterated dextromethorphan
MX2021000256A (es) Metodo de preparacion de inhibidor del factor de coagulacion xia e intermediario del mismo.
MX2020008488A (es) Forma cristalina del derivado de oxopicolinamida y metodo de preparacion del mismo.
IL289287A (en) Processes for making plasma kallikrein inhibitors
MX2019005723A (es) Inhibidor del receptor del factor de crecimiento de fibroblastos 4 (fgfr4) y metodo de preparacion y uso del mismo.
MX2023000970A (es) Metodo de preparacion de aminofuranos.
CL2021000663A1 (es) Proceso para la producción de gas de síntesis.
MX2022001549A (es) Nuevas sintesis telescopicas de 2-metoximetil-p-fenilendiamina.
MX2020005168A (es) Formas de dosificacion que contienen un inhibidor calicreina de plasma.
MX2019014989A (es) Proceso para la preparacion de (s,s)-secoisolariciresinol diglucosido y (r,r)-secoisolariciresinol diglucosido.
MX2021014245A (es) Procedimientos y productos intermedios para preparar un inhibidor de btk.
ZA202202879B (en) Process for preparing an e-selectin inhibitor intermediate
MX2022006984A (es) Procesos e intermediario para la preparacion de oxetan-2-ilmetanamina.